Skip to main content
Molecules logoLink to Molecules
. 2024 Oct 12;29(20):4840. doi: 10.3390/molecules29204840

Correction: Fan et al. Progress in the Preclinical and Clinical Study of Resveratrol for Vascular Metabolic Disease. Molecules 2022, 27, 7524

Dongxiao Fan 1,2, Chenshu Liu 1,2, Zhongyu Zhang 3,4, Kan Huang 1,2, Tengyao Wang 3,4, Sifan Chen 3,4, Zilun Li 1,2,*
PMCID: PMC11510409  PMID: 39459345

Text Correction

  • Figure 1 of the original publication [1]: the figure legend “PPARα: peroxisome proliferator-activated receptor-gamma coactivator-1α” should be “PPARα: peroxisome proliferator-activated receptor α”.

  • Original: PPARα: peroxisome proliferator-activated receptor-gamma coactivator-1α.

  • Correction: PPARα: peroxisome proliferator-activated receptor α.

  • The fourth paragraph of Section 2.1 in the original publication, “peroxisome proliferator-activated receptor-gamma coactivator-1α (PPARα)” should be “peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC1α)”.

  • Original: peroxisome proliferator-activated receptor-gamma coactivator-1α (PPARα).

  • Correction: peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC1α).

  • In the final paragraph of Section 2.2, “SIRT1-mediated activation of PPARα and its coactivator peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC1α)” should be “SIRT1-mediated activation of peroxisome proliferator-activated receptor α (PPARα) and its coactivator PGC1α”.

  • Original: SIRT1-mediated activation of PPARα and its coactivator peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC1α).

  • Correction: SIRT1-mediated activation of peroxisome proliferator-activated receptor α (PPARα) and its coactivator PGC1α.

The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Footnotes

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Reference

  • 1.Fan D., Liu C., Zhang Z., Huang K., Wang T., Chen S., Li Z. Progress in the Preclinical and Clinical Study of Resveratrol for Vascular Metabolic Disease. Molecules. 2022;27:7524. doi: 10.3390/molecules27217524. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Molecules are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES